[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"executive-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:executive-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,49,78,107,132,161,190,224,248,283,316,347,371,402,437],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100562884","epilepsy-journey-an-executive-functioning-intervention-for-teens-with-epilepsy-100562884",false,"NCT06608966","Epilepsy Journey-An Executive Functioning Intervention for Teens With Epilepsy","Epilepsy Journey 2.0: An Intervention to Improve Executive Functioning in Adolescents With Epilepsy","Inclusion Criteria:\n\n1. Age between 13-17 years at the time of enrollment\n2. Child lives at home with primary caregiver and is enrolled in school (excluding summer breaks).\n3. Confirmed diagnosis of epilepsy with seizures that are categorized as either generalized or focal in onset. Epilepsy is defined as: 1) At least two unprovoked seizures occurring more than 24-hours apart; or 2) One unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures.\n4. Primary language of English\n5. Screening Inclusion: On the parent-reported Behavior Rating Inventory of Executive Function-2nd edition (BRIEF-2), have executive functioning deficits defined as at least 2 subclinical (60\\\u003CT\\\u003C65) or one clinical BRIEF-2 subscale T scores (T≥65).\n6. Parent\u002Flegal guardian(s) willing to sign an IRB approved informed consent\n7. Participant willing to sign an Institutional Review Board approved assent\n\nExclusion Criteria:\n\n1. Parent or clinician-reported history in the adolescent of:\n\n   1. developmental delay (e.g., autism spectrum disorder, pervasive development disorder, history of services for developmental delay or intellectual impairment in the past 5 years, known IQ\\\u003C70)\n   2. severe mental illness (e.g., schizophrenia, bipolar disorder, eating disorder within the past 12 months, depression with active suicidal ideation or suicidal ideation\u002Fintent in the past 3 months)\n   3. prior (3-months) or current history of trauma and\u002For stressor-related disorders (e.g. PTSD)\n   4. recent or current significant medical disease (i.e., cardiovascular, hepatic, renal, gynecologic, musculoskeletal, metabolic or endocrine)\n   5. brain injury or brain tumor; and\u002For\n   6. epilepsy surgery\n   7. any other medical and\u002For psychological condition that takes treatment precedence over the study intervention\n2. Clinician-reported diagnosis in the adolescent of\n\n   1. epilepsy whose seizures are categorized only as either unknown onset or unclassified onset (defined as insufficient information to determine onset)\n   2. epilepsy currently being treated at the time of enrollment by 3 or more antiseizure medications (ASMs) (excluding rescue medication use)\n   3. epilepsy with a history of failure to achieve seizure freedom despite adequate use of 4 different anti-seizure medications\n   4. a confirmed or suspected epileptic encephalopathy (e.g., electrical status epilepticus in sleep, Landau Kleffner syndrome, West syndrome)\n   5. a confirmed or suspected progressive and degenerative disorder (e.g., mitochondrial disorders, metabolic disorders, autoimmune disorders)\n   6. one or more episodes of status epilepticus within the 24 weeks prior to enrollment; and\u002For\n   7. treatable causes of seizures, for example identified etiologies including metabolic, neoplastic, or active infectious origin.\n   8. non-epileptic event\u002Fseizures\n3. Adolescents currently on the ketogenic diet\n4. Participation in a trial of an investigational drug or device within 30 days prior to screening","ALL","13 Years","17 Years",{"count":20,"type":21},310,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this multi-site clinical trial is to determine the effectiveness of two components of a web-based intervention (Epilepsy Journey) to improve executive functioning in adolescents with epilepsy. The two components include web-based modules and problem-solving telehealth sessions with a therapist focused on executive functioning. This trial aims to answer the following questions:\n\n1. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving executive functioning in adolescents with epilepsy?\n2. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving quality of life in adolescents with epilepsy?\n\nParticipants will be randomly assigned to one of four groups: 1) Epilepsy Journey web-based modules and telehealth sessions, 2) Epilepsy Journey web-based modules only, 3) telehealth sessions with a therapist only, or 4) treatment as usual.\n\nParticipants will:\n\n* Independently review Epilepsy Journey web-based modules focused on executive functioning skills (\\~15-30 minutes) and\u002For have weekly telehealth sessions (\\~30-45 minutes) with a therapist for 14 weeks.\n* Complete measures of executive functioning (parent and teen-report) and quality of life (teen-report) at the start of the study, 14-, 26-, and 66- weeks after randomization. The NIH toolbox will be completed at the start of the study and 26-weeks after randomization. Additional measures will also be collected.",[27,28],"Epilepsy in Children","Executive Dysfunction",[30,31,32,33,34,35],"adolescents","executive functioning","seizures","epilepsy","behavioral trial","web-based intervention","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-25","ACTUAL",{"date":42,"type":40},"2024-11-11",{"date":44,"type":21},"2029-01-31",{"name":46,"class":47},"Children's Hospital Medical Center, Cincinnati","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":17,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100640267","intensive-neurofeedback-protocol-for-children-with-adhd-a-proof-of-concept-study-comparing-iapf-personalized-and-standard-theta-beta-ratio-training-100640267","NCT07595783","Intensive-neurofeedback Protocol for Children With ADHD: A Proof-of-concept Study Comparing iAPF-personalized and Standard Theta-beta-ratio Training","Inclusion Criteria:\n\n* Children aged 6-13 years. Confirmed ADHD diagnosis (ICD 10: F90.0, F90.1, or F98.8)\n* German-speaking children with normal or corrected vision.\n\nExclusion Criteria:\n\n* Children with neurological disorders (e.g., Epilepsy)\n* Children without an ADHD diagnosis\n* Caregivers with inability to provide informed consent or complete questionnaires\n* Participation in neurofeedback that was conducted in the year prior to the intended participation or is still ongoing.\n\nThe intake of medication or psychotherapeutic treatments and ICD-10 diagnosis are queried at T1, T2 and T3. These are recorded as control variables and are not exclusion criteria. The medication intake was kept constant during the NF training.","6 Years",{"count":57,"type":21},40,[24],"The first aim of this clinical trial is to test the feasibility and signal validity of a new approach to neurofeedback training (NF) using intensive EEG-based theta-beta NF for children with ADHD in the context of NF camps during school holidays. The second aim is to compare the efficacy of two neurofeedback protocols in reducing ADHD symptoms. Previous study results highlight that children with ADHD frequently show increased Theta-Beta-Ratios (TBR) in the qEEG, probably associated with attention difficulties, which may be ameliorated following neurofeedback training. However, the current state of research shows heterogenous findings regarding the efficacy of standard TBR NF for children with ADHD. Further study results suggest that personalized NF training protocols, based on the individual alpha peak frequency (iAPF), may be more effective in reducing ADHD symptoms than standardized ones.\n\nTherefore, in this proof-of-concept study of children with ADHD a standard TBR NF protocol is compared with an iAPF-personalized TBR NF (iAPF-TBR NF) protocol (based on the previously obtained iAPF). The study is designed as a randomized controlled intervention trial (RCT) with three assessment points (pre \\[T1\\], post \\[T2\\] and 6-month follow-up \\[T3\\]). Primary endpoints include the reduction of ADHD symptoms assessed by parent-, teacher- and self-report questionnaires. Furthermore, it is hypothesized that NF training is associated with better performance in a sustained attention and executive function test and a reduced TBR in qEEG, particularly following iAPF-TBR NF.\n\nThe main questions are:\n\n* Is it feasible to train groups of up to 12 children with two sessions NF per day for an eight-day-period during their school holidays?\n* Does iAPF-TBR NF provide a valid neuromodulatory signal compared to the standard-TBR-NF protocol? Do the frequency boundaries demonstrate spectral stability across the 16 training sessions?\n* Does the personalized iAPF-TBR NF training reduce ADHD symptoms measured immediately after the training more than standard-TBR-NF training? (comparison T2-T1)\n* Does the personalized iAPF-TBR NF training reduce ADHD symptoms measured 6 months after the NF training more than standard TBR-NF training? (comparison T3-T1)\n* Does the reduction in ADHD symptoms measured immediately after the NF-training persist until the 6-month follow-up? Do possible differences between iAPF-TBR NF training and standard TBR NF training remain? (comparison T3-T2)\n\nPost-hoc analyses of the courses are carried out. In addition, selectivity analyses will be carried out for clinical subgroups (e.g. different ADHD profiles)",[61,62,63,64,28],"ADHD","Inattention","Hyperactivity","Impulsivity",[66,61,67],"EEG-neurofeedback","children","2026-05-12",{"date":70,"type":40},"2026-05-19",{"date":72,"type":40},"2024-07-09",{"date":74,"type":21},"2026-12-31",{"name":76,"class":47},"Bielefeld University",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100610333","phase-1-methylphenidate-to-address-attention-and-executive-deficits-among-children-with-sickle-cell-disease-100610333","NCT07226219","Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","Pilot Trial of Stimulant Treatment to Address Attention and Executive Deficits Among Children With Sickle Cell Disease","Inclusion Criteria:\n\n* Diagnosed with SCD of any genotype\n* Enrolled on the institutional protocol: Sickle Cell Clinical Research Intervention Program (SCCRIP)\n* Between the ages of 8.0 and 17.9 years\n\n  \\*Included if performance measure, rating scale or diagnostic criteria met (within the past 2 years):\n* \\*Score at or below the 16th percentile on any 2 out of 4 performance measures:\n\n  * NIH Toolbox Flanker\n  * NIH Toolbox List Sorting\n  * NIH Toolbox Dimensional Change Card Sort Test (DCST)\n  * Wechsler Intelligence Scale for Children (WISC) -5\u002F Wechsler Adult Intelligence Scale (WAIS)-4 Digit Span Forward (DSF)\n* \\*Score at or above the 84th percentile on any 1 out of 2 parent rating scales:\n\n  * BRIEF-2 Global Executive\n  * BASC-3 Attention\n* \\*Have a documented diagnosis of attention deficit \u002F hyperactivity disorder (any subtype)\n* English as the primary language\n* Research participant and one parent willing to participate and provide consent\u002Fassent according to institutional guidelines\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* Primary language other than English\n* Score below the 2nd percentile on the Wechsler Abbreviated Scale of Intelligence (WASI)-2 intelligence quotient (IQ) test\n* Uncontrolled seizures (seizure within the past 6 months)\n* Cardiomyopathy or known congenital structural cardiac defects\n* Stenotic valvular disease, left coronary artery stenosis, or history of myocarditis or pericarditis\n* History of heart arrhythmia including ventricular tachycardia, ventricular fibrillation, supraventricular tachycardia, QT prolongation or concomitant use of medications associated with QT prolongation\n* Two or more prior episodes of priapism\n* Blood pressure \\>95th percentile at the three most recent visits consecutively (i.e., \\>95th percentile reading at all three of the most recent hospital visits to St. Jude).\n\n  * If blood pressure is \\> 95th %ile compared to age-norms on the day of the baseline visit, a repeat blood-pressure reading will be performed both electronically and manually to confirm findings.\n* Stimulant medication within the past two weeks\n* Severe sensory loss\n* Previous adverse reaction to methylphenidate\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n* Currently prescribed another investigational medication.\n* Currently prescribed any of the following:\n\n  * Phenobarbital (anticonvulsant)\n  * Phenytoin (anticonvulsant)\n  * Primidone (anticonvulsant)\n  * Warfarin (anticoagulant)\n  * Antipsychotic medications\n  * Selective Serotonin Reuptake Inhibitor (SSRI) medications\n  * Tricyclic antidepressant (TCA) medications\n  * Vasopressor medications","8 Years",{"count":87,"type":21},72,[89],"PHASE1","The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects.\n\nThe study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not.\n\nPrimary Objective:\n\n• Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits.\n\nSecondary Objective:\n\n• Evaluate neurobehavioral and safety outcomes following MPH treatment.\n\nExploratory Objective:\n\n• Evaluate decision-making and determinants influencing methylphenidate utilization among parents.",[92,28,93,94],"Sickle Cell Disease","Cognitive Impairment","Attention Deficit\u002FHyperactivity Disorder (ADHD)",[96,61],"SCD","2026-04-22",{"date":99,"type":40},"2026-04-23",{"date":101,"type":40},"2025-11-25",{"date":103,"type":21},"2028-08",{"name":105,"class":47},"St. Jude Children's Research Hospital",1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":106},"100478220","phase-2-a-digital-intervention-for-post-stroke-depression-and-executive-dysfunction-100478220","NCT05507138","A Digital Intervention for Post-Stroke Depression and Executive Dysfunction","Efficacy and Target Engagement of a Digital Intervention to Improve Depression and Executive Dysfunction After Stroke","Inclusion Criteria:\n\n* first-time stroke that occurred 6 months or more prior to study initiation\n* executive dysfunction as defined by a score of less than 1 standard deviation below age-adjusted normative score on at least one test of executive function in the screening assessment\n* diagnosis of Major Depressive Episode assessed by the Structured Clinical Interview for the DSM-5 (SCID).\n* at least moderate depressive symptoms as defined by Montgomery Asberg Depression Rating Scale ≥ 18\n* motor function sufficient to operate an iPad and use a pen, based on self-report and observation\n* if treated with an antidepressant medication, must be on a stable dose for a minimum of 8 weeks at the time of study enrollment.\n* able to adhere to all testing and study requirements and willingness to participate in the full study duration\n\nExclusion Criteria:\n\n* receptive aphasia as determined by a score of 2 or 3 on the NIH Stroke Scale \\[NIHSS\\] item 9 (\"Best Language\")\n* dysarthria that makes speech unintelligible (score of 2 on NIHSS item #10)\n* severe visual impairment or hemispatial neglect (score of 3 on NIHSS item #3 or score of 2 on NIHSS item #11)\n* patient already enrolled in ongoing concurrent cognitive rehabilitation (note that if a subject is already enrolled in psychotherapy, this will not be grounds for exclusion)\n* non-fluency in English\n* presence of or history of significant neurologic or neurodegenerative disorder other than stroke\n* presence of dementia based on dependence in basic ADLs due to cognitive deficits\n* history of psychosis or mania (evaluated using the SCID).\n* active suicide ideation (assessed via the Columbia Suicide Severity Rating Scale)\n* severe executive dysfunction (based on clinical judgment during screening evaluation) precluding use of the iPad\n* severe depression-even in the absence of active suicidal ideation-based on the screening evaluation and clinical judgment of the PI, which warrants a higher level of care and\u002For immediate referral to psychiatric services.\n* pregnancy\n* any other clinical or medical reason in the PI's initial screening evaluation that suggests the study is not appropriate for the participant.","50 Years","79 Years",{"count":117,"type":21},70,[119],"PHASE2","Individuals with stroke commonly experience both depression and cognitive difficulties. The goal of this study is to evaluate the efficacy of a treatment that combines a digital therapeutic (an iPad-based cognitive training program) with learning cognitive strategies. The hypotheses are that this treatment will improve cognitive skills, depression symptoms, daily function, and brain connectivity. In the short-term, the findings will inform the efficacy of the intervention and in the long-term, may support the use of the intervention to improve co-occurring cognitive and mood difficulties after stroke.",[28,122,123],"Depression","Stroke","2026-04-20",{"date":97,"type":40},{"date":127,"type":40},"2023-03-01",{"date":129,"type":21},"2026-09-30",{"name":131,"class":47},"Weill Medical College of Cornell University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":106},"100600037","transcranial-direct-current-stimulation-in-children-with-autism-100600037","NCT07092280","Transcranial Direct Current Stimulation in Children With Autism","A Pilot Study of Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder","tDCS","Inclusion Criteria:\n\n1. Males and females between 5 and 12 years with autism\n2. Enrolled in an ABA program (school or in-home) supervised by a Board Certified Behavior Analyst (BCBA)\n3. Stable medical and behavioral treatments for at least 4 weeks prior to, and during the study\n4. Able to tolerate wearing tDCS as determined during a week-long daily desensitization training.\n\nExclusion Criteria:\n\n1. Any implanted metal device (heart pacemaker, cochlear implant, surgical clips, etc.)\n2. Severe neurological disorders such as TBI, brain tumor, intracranial infection\n3. Seizure disorder with a seizure within the last two years\n4. Skull defect\n5. Peripheral blindness or deafness\n6. Medication that might affect tDCS: There have been a few studies concerning the effect of various medications on tDCS. Some may block and others may enhance the effects depending on many factors. The assay used to test these medications was its effect on the motor cortex after stimulation and this may not apply to our montages, however, in order to minimize the chances of having medication affect our results, participants taking the following medications will be excluded:\n\n   * Na or Ca channel blockers which will include all anti-seizure medications\n   * Medications that affect the NMDA receptors including dextromethorphan, cycloserine\n   * Serotonin reuptake inhibitors\n   * Dopamine stimulating or blocking medications including pergolide, bromocriptine and all antipsychotic medications\n   * Norepinephrine stimulating or blocking agents including propranolol and the stimulants\n   * Drugs that can lower seizure threshold \\[imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, phencyclidine, ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline\\]\n   * Barbiturates, benzodiazepines, meprobamate, chloral hydrate in the past 4 weeks\n7. Acute skin disease\n8. History of magnetic or electrical stimulation","5 Years","12 Years",{"count":143,"type":21},24,[24],"Although many children diagnosed with autism spectrum disorder (ASD) make significant progress in learning and their cognitive skills improve with applied behavior analysis (ABA), there are a significant number of children who show an absence or a plateau in various skills. Deficits in executive functioning are likely to be involved in many of these cognitive and learning disabilities due to poor functioning of the prefrontal cortex. Currently, the use of biological methods for improving learning and cognition is largely unexplored in research and practice.\n\nThe aim of this study is to use of transcranial direct current stimulation (tDCS) in combination with ABA to improve the acquisition of educational programs for students with ASD. tDCS is a low-level electrical neurostimulation and is most effective when used in combination with an active training or teaching, facilitating the neuronal circuits used for that task.\n\ntDCS has been used for various indications over a couple of decades and has been shown to be very safe and has been well-tolerated by children with ASD. The mechanism of tDCS is not clear, however animal studies show that tDCS can stimulate the flow of calcium ions through channels in the astrocytes, activating them, and facilitating their role in synapse formation and therefore learning.",[147,28],"Autism Spectrum Disorder",[149,150],"transcranial direct current stimulation","applied behavior analysis","2026-02-19",{"date":153,"type":40},"2026-02-23",{"date":155,"type":21},"2026-04-01",{"date":157,"type":21},"2029-12",{"name":159,"class":160},"New York State Institute for Basic Research","OTHER_GOV",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":16,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":106},"100525828","causal-role-of-the-aperiodic-signal-for-working-memory-100525828","NCT06126809","Causal Role of the Aperiodic Signal for Working Memory","TRAS","Inclusion Criteria:\n\n* Between the ages of 18 and 35\n* Able to provide informed consent\n* Normal or corrected-to-normal vision\n* Willing to comply with all study procedures and be available for the duration of the study\n* Ability to speak, read and understand English without a translator\n* Not color-blind\n\nExclusion Criteria:\n\n* ADHD\u002FADD (currently under treatment)\n* Neurological disorder and conditions\n* Medical or neurological illness or treatment for a medical disorder that could interfere with study participation, e.g., unstable cardiac disease, HIV\u002FAIDS, malignancy, liver or renal impairment\n* Prior brain surgery\n* Any brain devices\u002Fimplants, including cochlear implants and aneurysm clips\n* History of traumatic brain injury\n* (For females) Pregnant\n* Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study\n* Current use of medications know to produce specific EEG activity known to disrupt interpretations of the findings including but not limited to: benzodiazepines, antipsychotics, antiepileptics and central nervous system stimulants",true,"18 Years","35 Years",{"count":172,"type":21},30,[24],"Working memory (WM) is the ability to hold relevant information in mind in the absence of sensory input. The capacity for WM is a foundation for cognitive control and higher cognitive function more broadly. Previous research demonstrated that during the delay period of WM tasks, oscillatory electrical activity in the prefrontal cortex in the theta-frequency band (4-8 Hz) increased in amplitude. However, other groups found that the slope of the aperiodic signal in the brain was positively correlated with individual differences in WM capacity. Since low-frequency power and a steeper slope of the aperiodic signal are confounded in many analyses, it is not clear whether the slope of the aperiodic signal or the amplitude of low-frequency oscillations underlie WM capacity. With many studies investigating the causal role of theta oscillations in WM, the purpose of this project is to investigate the role of the aperiodic signal in WM performance.",[28],[177,178,179,180],"cognitive control","working memory","electroencephalography","transcranial electrical stimulation","2026-01-09",{"date":183,"type":40},"2026-01-12",{"date":185,"type":40},"2024-03-25",{"date":187,"type":21},"2026-12",{"name":189,"class":47},"Florida State University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":198,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":208,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":106},"100490050","non-invasive-brain-stimulation-for-cognitive-and-motor-dysfunction-in-dementia-100490050","NCT05661084","Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia","Multifocal Transcranial Current Stimulation for Cognitive and Motor Dysfunction in Dementia","ACDCStim","Inclusion Criteria:\n\nParticipants (Ps)\n\n* willing and capable to give informed consent for the participation in the study after it has been thoroughly explained\n* able and willing to comply with all study requirements\n* an informed consent form was signed\n* able to read, write, and communicate in English\n\nCaregiver\u002FAdministrators (As)\n\n* at least 18 years of age\n* able to read, write, and communicate in English\n* self-reported computer proficiency and willingness to learn how to use tES as defined by \"yes\" answers to the questions \"Do you feel comfortable using a computer?\" and \"Are you willing to be the primary caregiver for a participant and learn how to administer tES?\"\n* stated availability during weekdays throughout the study period to administer tES to the Ps\n\nExclusion Criteria:\n\nParticipants (Ps)\n\n* major psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis\n* blindness or other disabilities that prevent task performance\n* contraindications to tES, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, etc.)\n* the presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen\n* an inability to understand study procedures following review of the Informed Consent form\n* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator\n\nCaregiver\u002FAdministrators (As)\n\n* mild cognitive impairment defined by a MoCA score ≤26 during the in-person screen\n* insufficient understanding of study procedures following review of the Informed Consent form\n* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.\n* poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tES","55 Years",{"count":200,"type":21},144,[24],"This project aims to examine the efficacy of remote, caregiver-led tES\u002Fbrain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.",[204,205,206,28,207],"Dementia","Memory Loss","Alzheimer Disease","Mobility Limitation",[209,204,210,211,212,213,214,215],"Alzheimer's Disease","Memory","Brain Stimulation","transcranial alternating current stimulation (tACS)","transcranial direct current stimulation (tDCS)","Executive function","instrumental activities of daily living (IADL)","2026-01-08",{"date":183,"type":40},{"date":219,"type":40},"2023-01-24",{"date":221,"type":21},"2027-08-31",{"name":223,"class":47},"Hebrew SeniorLife",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":168,"sex":16,"minAge":17,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":246,"locationsCount":77},"100563939","integrative-adolescence-research-programme-iarp-100563939","NCT06622681","Integrative Adolescence Research Programme (IARP)","Integrative Adolescence Research Programme (IARP) - iAdoRe Study","IARP","Inclusion Criteria:\n\n1. Aged 13 to 15 years of age\n2. Currently studying in MOE registered school\n3. Part of the DREAMS study\n\nExclusion Criteria:\n\n1. Not in MOE registered school\n2. Not part of the DREAMS study","15 Years",{"count":234,"type":21},1200,"OBSERVATIONAL","This study aims to understand child health during adolescence. We will examine the role of lifestyle (e.g. physical activity), growth trajectories and other environmental factors that can influence the development of phenotypes in adolescence which confer risk for later physical and mental disorders. With this study, we will develop a deeper understanding of adolescent health and well-being and their main determinants in the local Singaporean context, identify levers for early interventions to mitigate challenges to adolescent health and well-being and enhance protective factors for adolescents to do well in life, contribute to society and maximize their potential.",[28,238,239],"Physical Stress","Mental Health Wellness 1","2025-12-22",{"date":242,"type":40},"2025-12-30",{"date":244,"type":40},"2024-05-21",{"date":187,"type":21},{"name":247,"class":47},"Institute for Human Development and Potential (IHDP), Singapore",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":256,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":262,"conditions":263,"keywords":268,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":106},"100424030","phase-3-goal-directed-sedation-in-mechanically-ventilated-infants-and-children-100424030","NCT04801589","Goal-Directed Sedation in Mechanically Ventilated Infants and Children","Maximizing Efficacy of Goal-Directed Sedation to Reduce Neurological Dysfunction in Mechanically Ventilated Infants and Children Study","mini-MENDS","Inclusion Criteria:\n\n* Patients will be eligible for enrollment if they are 1) aged 44 weeks post-menstrual age and up to 11 years, 2) planned admission to the pediatric ICU at Monroe Carell Jr. Children's Hospital at Vanderbilt (MCJCHV), and 3) requiring mechanical ventilation (MV) and sedation. Pre-pubescent children (\\\u003C11 years) are typically different from older children who often behave physiologically more similar to adults. Pre-pubescent children are more likely to be admitted to the PICU and are undergoing a steeper curve of neurocognitive maturation. Therefore, these patients may be at greatest risk for worse brain dysfunction.\n\nExclusion Criteria: Patients will be excluded (i.e., not approached for consent) if any one is present:\n\n1. Receiving continuous sedation for \\> 72 hours prior to screening.\n2. Rapidly resolving respiratory failure at screening, with planned immediate liberation from MV.\n3. Severe developmental delay at baseline defined as a score of ≥ 4 (severe disability) on the Pediatric Cerebral Performance Category (PCPC) Scale, referencing cognitive status prior to critical illness.\n4. Clinically significant 2nd or 3rd degree heart block or bradycardia \\\u003C 60 beats per minute.\n5. Benzodiazepine dependency with ongoing medical requirement of continuous benzodiazepine (infusion).\n6. Inability to co-enroll with another study.\n7. Expected death or care plan for withdrawal of support measures within 24 hours of enrollment.\n8. Bilateral vision loss.\n9. Deafness that will preclude delirium evaluation.\n10. Inability to understand English that will preclude delirium evaluation. The inability to understand English in verbal participants will not result in exclusion when the research staff is proficient and\u002For translation services are actively available in that particular language.\n11. Documented allergy to either dexmedetomidine or midazolam.\n12. Medical requirement of continuous (infusion) neuromuscular blockade administration that is planned ongoing for at least 48 hours at time of screening.\n13. Inability to start the informed consent process within the 72 hours from the time that all inclusion criteria were met (possible reasons):\n\n    1. Attending physician refusal\n    2. 72-hour period of eligibility was exceeded before the patient was enrolled\n    3. Legal Authorized Decision Maker (e.g. legal guardian\u002Fpower of attorney) refusal\n    4. Legal Authorized Decision Maker (e.g. legal guardian\u002Fpower of attorney) unavailable\n    5. Legal Authorized Decision Maker (e.g. legal guardian\u002Fpower of attorney) is non-English speaking and available research staff is not proficient and\u002For translation services are not available in that particular language.\n14. Adjusted dosing weight is \\> 50 kg at time of screening.","44 Weeks","11 Years",{"count":259,"type":21},372,[261],"PHASE3","Ventilated pediatric patients are frequently over-sedated and the majority suffer from delirium, a form of acute brain dysfunction that is an independent predictor of increased risk of dying, length of stay, and costs. Universally prescribed sedative medications-the GABA-ergic benzodiazepines-worsen this brain organ dysfunction and independently prolong duration of ventilation and ICU stay, and the available alternative sedation regimen using dexmedetomidine, an alpha-2 agonist, has been shown to be superior to benzodiazepines in adults, and may mechanistically impact outcomes through positive effects on innate immunity, bacterial clearance, apoptosis, cognition and delirium. The mini-MENDS trial will compare dexmedetomidine and midazolam, and determine the best sedative medication to reduce delirium and improve duration of ventilation, and functional, psychiatric, and cognitive recovery in our most vulnerable patients-survivors of pediatric critical illness.",[264,265,266,28,267],"Delirium","Critical Illness","Sedation Complication","Post Traumatic Stress Disorder",[269,270,271,272,273],"pediatrics","critical care","agitation","sedation","delirium","2025-09-23",{"date":276,"type":40},"2025-09-29",{"date":278,"type":40},"2021-05-10",{"date":280,"type":21},"2026-09-16",{"name":282,"class":47},"Vanderbilt University Medical Center",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":300,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":77},"100380089","computer-assisted-self-training-to-improve-executive-function-100380089","NCT04229056","COMPuter-assisted Self-training to Improve EXecutive Function","Computer-Assisted Self-Training to Improve Executive Function Versus Unspecific Training in Patients After Stroke, Cardiac Arrest or in Parkinson's Disease: a Randomized Controlled Trial","COMPEX","Inclusion Criteria:\n\n* A diagnose of stroke, cardiac arrest or Parkinson's disease.\n* Aged 18 years or older.\n* Impaired working memory measured with CABPad working memory test, cut off for inclusion: 5 symbols or less backwards\n* Computer and internet access at home.\n* Providing informed consent.\n\nInclusion criteria specific for stroke\n\n* Inclusion within 6 months post-stroke\n* Stroke confirmed by clinical findings and imaging, both AIS and ICH is allowed.\n* Initial stroke severity \\>\u002F= NIHSS 3.\n\nInclusion criteria specific for cardiac arrest\n\n• Inclusion within 6 months post ictus.\n\nInclusion criteria specific for Parkinson's disease\n\n* Clinical diagnosis of PD.\n* Anti-parkinsonian medical treatment (dopaminergic or other).\n\nExclusion Criteria:\n\n* Informed consent not provided\n* Other neurological or psychiatric disease which is expected to influence the patient's ability to participate in the trial according to the investigator\n* Not able to participate according to investigator\n\nExclusion criteria specific for stroke\n\n* Patients with massive anosognosia for executive dysfunction or patients with no subjective feeling of executive dysfunction (Patient sustains total denial of executive symptoms over time)\n* Patients with severe aphasia, in which it is unclear whether the patient's performance on a neuropsychological test-battery is due to aphasia and not executive dysfunction.\n\nExclusion criteria specific for cardiac arrest • None\n\nExclusion criteria specific for PD\n\n• Diagnosis of PD Dementia according to the MDS PD Dementia criteria","100 Years",{"count":293,"type":21},307,[24],"This project explores the effects of specialized computer-based cognitive rehabilitation (CBCR) targeting executive functions in three groups of patients: Stroke, Cardiac Arrest and Parkinson's Disease. The effect of specialized CBCR is compared to generally cognitively stimulating activities on a computer",[297,123,298,299,28],"Parkinson Disease","Cardiac Arrest","Cognitive Dysfunction",[301,302,303,304,305,306],"parkinson disease","stroke","cardiac arrest","executive dysfunction","cognitive dysfunction","computer-based cognitive rehabilitation","2025-02-19",{"date":309,"type":40},"2025-02-20",{"date":311,"type":40},"2020-06-01",{"date":313,"type":21},"2026-06-30",{"name":315,"class":47},"Bispebjerg Hospital",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":326,"conditions":327,"keywords":332,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":48},"100495095","profiling-the-dynamic-of-binge-eating-disorder-prody-bed-100495095","NCT05726721","Profiling the Dynamic of Binge Eating Disorder (PRODY-BED)","Profiling the Dynamic of Binge Eating Disorder (BED): a Longitudinal Study Examining the Influence of Emotion Regulation, Executive Function, Eating Pattern on BED and Outcome (PRODY-BED)","PRODY-BED","Inclusion Criteria:\n\n* Age 18+,\n* diagnosed with Binge eating Disorder,\n* and offered treatment at on of the inclusion sites.\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidity (e.g. psychosis, severe developmental disorder, severe cogntive impairement)",{"count":325,"type":21},180,"The goal of this observational study is to explore if different and specific profiles can be identified in adults with binge eating disorder (BED) depending on their additional eating pathology, emotion regulation and executive functions. The main questions it aims to answer are:\n\n* Is there different and specific subgroups of patients with BED according to baseline profiles in emotion regulation, executive function and additional eating pathology (including restriction, chaotic eating, grazing and eating on external cues)?\n* Are subgroups of individuals with BED (based on identified profiles) associated with outcome at end of treatment and follow-up?\n* What is the trajectories in remission rates of specific symptom dimensions (eating disorder pathology, emotion regulation, executive function, and depressive symptoms) in individuals with BED and is there specific trajectory profiles in these dimensions?\n* Is early changes in specific symptom dimensions (eating pathology, emotion regulation, executive function, or depression) associated with outcome of BED? Participants will be asked to fill in questionnaires before treatment as usual, 10 weeks into treatment, at end of treatment and at 6- and 12-month follow-up.",[328,329,28,330,331],"Binge-Eating Disorder","Emotion Regulation","Eating Behavior","Depressive Symptoms",[333,334,335,336,337],"psychotherapy","Adults","binge eating disorder","emotion regulation","executive function","2025-02-04",{"date":340,"type":40},"2025-02-06",{"date":342,"type":40},"2023-07-03",{"date":344,"type":21},"2028-05-31",{"name":346,"class":47},"Aarhus University Hospital",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":257,"maxAge":18,"enrollmentInfo":354,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":106},"100576190","idiopathic-generalized-epilepsy-cognitive-and-emotional-profile-100576190","NCT06782074","Idiopathic Generalized Epilepsy Cognitive and Emotional Profile","Idiopathic Generalized Epilepsy: Cognitive, Emotional, Behavioral Functioning, and Quality of Life","Inclusion criteria:\n\nAge between 11 and 18 years Diagnosis of idiopathic generalized epilepsy\n\nExclusion criteria:\n\nAge under 11 years or over 18 years Structural or cryptogenic epilepsy Intellectual disability or borderline cognitive level Refusal to participate in the study Failure to obtain informed consent",{"count":355,"type":21},96,"The primary goal of the study is to explore the neurocognitive, emotional-behavioral functioning, and quality of life of adolescents with IGE, identifying key factors that affect their overall well-being.\n\nThe study involves participants and their caregivers completing standardized questionnaires. Additionally, clinical and anamnesic information will be collected to investigate the role of these variables on the emotional and executive functioning of the enrolled subjects",[358,359,360,361,28],"Epilepsy","Quality of Life","Neuropathology","Emotional Problem","2025-01-13",{"date":364,"type":40},"2025-01-17",{"date":366,"type":40},"2023-06-01",{"date":368,"type":21},"2025-06-30",{"name":370,"class":47},"IRCCS National Neurological Institute \"C. Mondino\" Foundation",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":16,"minAge":379,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":388,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":48},"100536638","learning-by-heart-the-effectiveness-of-an-ef-training-program-for-pre-schoolers-with-a-severe-chd-100536638","NCT06267430","Learning by Heart: The Effectiveness of an EF Training Program for Pre-schoolers With a Severe CHD","The Effectiveness of a Personalized Executive Functioning Training Program for Pre-schoolers With a Severe Congenital Heart Disease","LbH","In order to be eligible to participate in this study, a child must meet all of the following criteria:\n\n* Aged 4.0 - 6.0 years upon inclusion OR aged 6.0-7.0 years who are still in kindergarten (group 1 \\& 2 of the Dutch school system)\n* Required CHD surgery in the first six months of life (with or without ECMO) or a cyanotic CHD that required surgery in the first 12 months of life\n* IQ estimated \\> 55 (no moderate to severe intellectual disability)\n* Diminished EF based on a below average score on any of the subtests of the 'KleuterExtra' test battery (≤ 25 percentile) at t = 0\n* Sufficient comprehension of the Dutch language by the child to be able to participate in the EF test battery and the EF training program. In order to be eligible to participate in this study, the parent(s) must meet the following criteria:\n* Sufficient comprehension of the Dutch language to understand the study information and to be able to fill out the Dutch questionnaires.\n\nExclusion Criteria:\n\n* Children receiving targeted EF support at school upon inclusion.\n* Children with severe brain damage (estimated IQ \\\u003C 55)\n* Genetic syndromes known to directly affect cognitive performance (e.g. Down syndrome)\n* Children with severe psychiatric disorders upon inclusion that require treatment first, such as a posttraumatic stress disorder, separation anxiety disorder, or reactive attachment disorder.","4 Years","7 Years",{"count":382,"type":21},141,[24],"Advances in prenatal and neonatal care have improved outcomes in children with severe congenital heart disease (CHD). With the increase in survival, neurocognitive problems such as executive functioning (EF) impairments have become more apparent in these children. EF problems have cascading negative effects on a child's development. New insights in EF development suggest that in otherwise physically healthy young children, EF can be improved by training. In a pilot study funded by Stichting Hartekind, the investigators studied the feasibility of a personalized EF training program called 'Kleuter Extra' and the results were promising. Therefore, the current study will investigate the effectiveness of this program in 4-6-year-old children with severe CHD. The researchers will also explore interactions between the parent-child relationship and EF development of the child as psychosocial difficulties in these children and their parent(s) and\u002For caretaker(s) may impact EF-development. If found effective, EF training for children with severe CHD will improve their developmental outcome.",[386,28,387],"Congenital Heart Disease","Attention Disorder",[389,390,391,392],"Congenital heart disease","Preschooler","Executive functions","Training","2024-11-26",{"date":395,"type":40},"2024-11-29",{"date":397,"type":40},"2024-05-01",{"date":399,"type":21},"2027-12-31",{"name":401,"class":47},"Erasmus Medical Center",{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":435,"locationsCount":106},"100452294","computerized-cognitive-rehabilitation-of-executive-deficits-in-stroke-patients-100452294","NCT05169632","Computerized Cognitive Rehabilitation of Executive Deficits in Stroke Patients","Combined Cognitive and Physical Training for the Neurorehabilitation of Executive Deficits After Stroke: an Exploratory Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ischemic or haemorrhagic cerebral stroke ≥ 8 weeks before study inclusion\n* Cognitive complaint and\u002For clinical impression of dysexecutive syndrome\n* Z-Score \\\u003C -1.0 in at least two of the following domains\n\n  * Cognitive flexibility (Trail-Making Test B\u002FA)\n  * Cognitive interference (Stroop color word interference task)\n  * Divided attention (TAP divided attention)\n  * Working memory (TAP working memory, Forward Digit Span, Backward Digit Span)\n  * Design fluency (Five-points test)\n\nExclusion Criteria:\n\n* Major neurocognitive disorder according to the DSM-5\n* Proximal extremity paresis grade \\\u003C M4 on the Medical Research Council (MRC) Scale for Muscle Strength in at least one of four extremities\n* Insufficient visual acuity, visual field or hemispatial attention to engage in the training\n* Inability to discriminate colour: \\\u003C 12 points on the Ishihara test\n* Changes over the last 4 weeks in antidepressive, anxiolytic or in acetylcholinesterase inhibitor drugs\n* Thoracic pain and\u002For heart palpitations at rest, during or following a physical effort (based on self-report)\n* Clinically unstable cardio-vascular disease\n* Falls in the past 12 weeks as evaluated in the enrolment interview \\[Hopkins Falls Grading Scale (Grade \\>1)\\]\n* High risk of falling according to a score of over 15 seconds on the Four Square Step Test (FSST)\n* Insufficient knowledge or capacity of French to follow instructions\n* Incapacity or unwillingness to provide informed consent",{"count":410,"type":21},32,[24],"WHO: 32 participants with executive deficits related to a stroke, able to engage in moderate physical activity.\n\nWHY: Around one third of stroke patients suffer from cognitive deficits in the long term, which have a detrimental impact on everyday personal and professional life. The purpose of this study is to evaluate two sets of computerized exercises combining cognitive and physical effort to see if they can improve executive function.\n\nWHAT: Study participants first undergo cognitive and physical assessments. Additional questionnaires will assess mood, everyday life cognition, function and quality. This will be followed by a 6 week training period with 3 training sessions a week. The effect of the cognitive and physical training will be measured in a post-training evaluation session. Six months after completion of the training, the study will evaluate cognitive and physical abilities of participants to study long-term effects of the respective training program.\n\nWHERE: Both the evaluation and the training sessions will be conducted on the premises of the Centre Hospitalier Universitaire Vaudoise (Pavillon 4, Avenue de Beaumont, 1005 Lausanne, Switzerland)",[123,28],[415,416,417,418,419,420,421,422,423,424,425,426,427,428],"Stroke Rehabilitation","Neurological Rehabilitation","Exercise Therapy","Brain Training","Nervous System Diseases","Neurocognitive Disorders","Cognition Disorders","Mental Disorders","Vascular System Injuries","Cerebrovascular Disorders","Multimodal Intervention","e-Health","Digital Intervention","Exergame","2024-08-12",{"date":431,"type":40},"2024-08-13",{"date":433,"type":40},"2022-03-17",{"date":368,"type":21},{"name":436,"class":47},"Centre Hospitalier Universitaire Vaudois",{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":16,"minAge":444,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":453,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":106},"100466659","engage-for-late-life-depression-and-comorbid-executive-dysfunction-100466659","NCT05356611","Engage for Late-Life Depression and Comorbid Executive Dysfunction","Engage: A Treatment for Late-Life Depression and Comorbid Executive\u002FCognitive Dysfunction","Inclusion Criteria:\n\n* Age 60 or older\n* Ability to read, write, and speak English\n* Located in Las Vegas or surrounding area\n* Ability to travel to UNLV campus by self or possible caregiver for regular study visits\n* Clinically significant symptoms of depression as evidenced by: 1) Scores \\> 5 on the Geriatric Depression Scale-Short Form (GDS-SF)\n* Mild cognitive impairment as evidenced by: 1) Scores \\> 18 and \\\u003C 25 on the Montreal Cognitive Assessment (MoCA)\n\nExclusion Criteria:\n\n* Active suicidal ideation\n* History of suicide attempt(s)\n* Current symptoms of: 1) Psychosis; 2) Active substance use disorder\n* Reported history of: 1) Bipolar disorder (\"manic depression\"); 2) Intellectual disability\n* Currently in or scheduled to initiate individual psychotherapy to avoid treatment interference\n* Psychotropic medication permitted if dose was stable over the past 2 weeks\n* Currently living in an institutional setting (e.g., assisted living, inpatient, skilled nursing)\n* Presence of notable memory-specific cognitive deficits as evidenced by: scores \\\u003C 9 on the MoCA memory subscale (rendering it difficult to participate in and track\u002Frecall events for weekly psychotherapy)","60 Years",{"count":446,"type":21},20,[24],"Although there are an increasing number of mental health treatment adaptations for older adults, there are still a number of factors to consider when making these adaptations. Cognitive decline is one such factor that places significant burden on older adults and can interfere with traditional mental health therapies. Engage is a behavioral treatment approach that has shown to be effective in treating late life depression. The investigators are testing the feasibility of Engage as a treatment method for late life depression in older adults with cognitive decline. The objective is to corroborate Engage as an alternative late life depression treatment method for a sub-population of older adults with cognitive decline. Cognitive decline poses a unique mental health treatment barrier that is often over looked in younger populations. With a relatively higher prevalence of cognitive decline in older adulthood, it is imperative that a feasible mental health treatment program that can be effective in the presence of cognitive decline.",[450,451,452,28],"Depression in Old Age","Psychotherapy","Mild Cognitive Impairment",[454,455],"Older Adults","Late-Life Depression","2024-08-04",{"date":458,"type":40},"2024-08-06",{"date":460,"type":40},"2023-09-24",{"date":462,"type":21},"2025-05",{"name":464,"class":47},"University of Nevada, Las Vegas"]